We are among the elite 1% NCI-designated comprehensive cancer centers in the U.S. — and we are ranked in the top 1% of all U.S. hospitals for cancer care, according to U.S. News & World Report.
Cancer Clinical Trials
- Blood & Bone Marrow Cancers
- Brain, Spine & Central Nervous System Cancers
- Breast Cancer
- Childhood Cancers
- Endocrine System Cancers
- Gastrointestinal (GI) Cancers
- Genitourinary (GU) & Urologic Cancers
- Gynecologic Cancers
- Head & Neck Cancers
- Kaposi Sarcoma & AIDS-Related Cancers
- Lung & Chest Cancers
- Prostate Cancer
- Sarcomas
- Skin Cancer
Treating More Than 200 Types of Cancer
Over 500 Active Clinical Trials
Navigating Your Cancer Care
At Montefiore Einstein Comprehensive Cancer Center, you receive evidence-based cancer care that addresses the unique needs of each individual patient. Our NCI-designated comprehensive cancer center brings the worlds of clinical care and academic research together and allows for the translation of novel, leading-edge scientific discoveries into improved clinical outcomes and new life-saving treatments.
Using a multidisciplinary team of disease-focused experts, our full-service cancer center is focused on the prevention, early diagnosis and treatment of cancer while incorporating a comprehensive spectrum of traditional and holistic care. This allows us to deliver highly specialized and coordinated compassionate care for the whole person, address complex medical needs and improve the quality of life for each and every patient.
Over 50 Years of Cancer Research & Treatment Breakthroughs
Our Latest Research
Advancing human health, scientific discovery and innovation through cancer research
News Release
Montefiore Einstein’s Marina Konopleva Joins Break Through Cancer TeamLab
Leaders in the Science of Cancer Care
At Montefiore Einstein Comprehensive Cancer Center, we’re committed to finding new and better cancer treatment options.
Our research breakthroughs continue to lead to game-changing cancer treatment practices and give patients a chance to join upcoming clinical trials, which may offer potentially successful treatment options. We’ve received accreditation from the NCI for the past 50 years in a row. Our facility is one of only 71 NCI-designated centers across the United States-and the only one located between Manhattan and New Haven. We made that expansion from Manhattan to Westchester to provide convenient access to cancer patients across the region.
State-of-the-Art Technology
At Montefiore Einstein Comprehensive Cancer Center, we are proud to provide patients with the newest technology available and offer the latest surgical and therapeutic techniques. Our goal is to utilize the least invasive solutions for your cancer care.
That is why we offer the latest in image-guided, immuno-, cellular and targeted therapies, to name just a few.
Some of our other molecular imaging technology includes the latest three-dimensional systems for bioluminescence imaging (BLI), fluorescence molecular imaging (FMI), positron emission tomography (PET) and single-photon emission computed tomography (SPECT).
Committed to Moving Faster Than Cancer
Cancer Center Highlights Report
Our Highlights Report documents our remarkable innovations in research, treatment and care.
-
$82M
in cancer relevant funding, of which $33 million is dedicated to philanthropy
-
1000+
patients enrolled in clinical research studies
-
400
papers published annually in high impact peer-reviewed journals
-
200+
types of cancer treated
Meet Your Cancer Care Team
Montefiore Einstein Comprehensive Cancer Center is home to 14 teams of award-winning, multidisciplinary experts who will develop a highly personalized treatment plan specific to your particular type of cancer, including those considered rare.
Events at Montefiore Einstein Comprehensive Cancer Center
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
-
Conditions
Breast Cancer
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects with Relapsed/Refractory Hematologic Malignancies
-
Conditions
Multiple Hematologic Malignancies
Phase I/II Study of Rapcabtagene Autoleucel in CLL/SLL, 3L DLBCL, R/R ALL and 1L HR LBCL
-
Conditions
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Acute Lymphocytic Leukemia
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment with the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
-
Conditions
Endometrial Cancer
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
-
Conditions
Limited-Stage Small-Cell Lung Cancer
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
-
Conditions
Multiple
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
-
Conditions
Lung Cancer
- Urothelial/Bladder Cancer
Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
-
Conditions
Urothelial/Bladder Cancer
